FDA
-
-
-
-
-
-
-
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
-
-
-
-
-
-
-
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
-
-
-
-
-
-
-
Precigen reports sustained responses for RRP therapy PAPZIMEOS
-
-
-
-
-
-
-
Precigen Reports First Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Precigen Inc. (PGEN) Appoints Phil Tennant as Chief Commercial Officer
-
-
-
-
-
-
-
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
-
334,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


